[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100496588":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":22,"centralContacts":26,"locations":32,"responsibleParty":77,"collaborators":79,"id":83,"slug":84,"hasResults":85,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":85,"sex":90,"minAge":91,"maxAge":10,"enrollmentInfo":92,"targetDuration":10,"studyType":95,"phases":10,"briefSummary":96,"conditions":97,"keywords":99,"overallStatus":35,"whyStopped":10,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":111},{"fullName":5,"class":6},"University of California, San Francisco","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Participants with Pancreatic Neuroendocrine Neoplasms",null,[12],"Diagnostic Test: Hereditary Cancer Panel",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"DIAGNOSTIC_TEST","Hereditary Cancer Panel","UCSF's Internal Clinical Laboratory Improvement Amendments of 1988 (CLIA)-certified Expanded Hereditary Cancer Panel will be employed which measures a minimum 88 genes",[9],[20,21],"University of California, San Francisco's (UCSF) Expanded Hereditary Cancer Panel","Germline Testing",[23],{"name":24,"affiliation":5,"role":25},"Emily Bergsland, MD","PRINCIPAL_INVESTIGATOR",[27],{"name":28,"role":29,"phone":30,"phoneExt":10,"email":31},"Bryan Le","CONTACT","(415) 502-6313","bryankhuong.le@ucsf.edu",[33,50,62],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"University of California, Los Angeles","RECRUITING","Los Angeles","California","90095","United States","US",{"type":42,"coordinates":43},"Point",[44,45],-118.24368,34.05223,{"lat":45,"lon":44},[48],{"name":49,"role":25,"phone":10,"phoneExt":10,"email":10},"Randy Hecht, MD",{"facility":51,"status":35,"city":52,"state":37,"zip":53,"country":39,"countryCode":40,"cosmosGeoPoint":54,"geoPoint":58,"contacts":59},"Univeristy of California, San Diego","San Diego","92093",{"type":42,"coordinates":55},[56,57],-117.16472,32.71571,{"lat":57,"lon":56},[60],{"name":61,"role":25,"phone":10,"phoneExt":10,"email":10},"Paul Fanta, MD",{"facility":5,"status":35,"city":63,"state":37,"zip":64,"country":39,"countryCode":40,"cosmosGeoPoint":65,"geoPoint":69,"contacts":70},"San Francisco","94143",{"type":42,"coordinates":66},[67,68],-122.41942,37.77493,{"lat":68,"lon":67},[71,73,76],{"name":28,"role":29,"phone":72,"phoneExt":10,"email":31},"415-502-6313",{"name":10,"role":29,"phone":74,"phoneExt":10,"email":75},"877-827-3222","cancertrials@ucsf.edu",{"name":24,"role":25,"phone":10,"phoneExt":10,"email":10},{"type":78,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[80],{"name":81,"class":82},"University of California Pancreatic Cancer Consortium (UCPCC)","UNKNOWN","100496588","genetic-predisposition-testing-program-for-pancreatic-neuroendocrine-neoplasms-100496588",false,"NCT05746182","Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms","PanNEN","Inclusion Criteria:\n\n1. Histologically confirmed PanNEN.\n\n   a. The diagnostic biopsy may have been taken from any site (primary or metastatic).\n2. New and existing PanNEN participants will be eligible (any grade, any stage, any age \\> 18 years).\n3. Participants willing and able to comply with the study procedures.\n\nExclusion Criteria:\n\n1. Inability to provide informed consent.\n2. For participants who have not had prior testing with a dedicated germline pane of at least 80 genes:\n\n   1. Inability to speak\u002Fread a language supported by the germline testing station (GTS). The supported languages currently include English, Korean, Japanese, Vietnamese, Russian, Tagalog, Farsi, Spanish, Cantonese, Mandarin, and Arabic).\n   2. Active hematologic malignancy.\n   3. History of allogenic bone marrow transplant or stem cell transplant.","ALL","18 Years",{"count":93,"type":94},300,"ESTIMATED","OBSERVATIONAL","This is a prospective observational multi-center pilot study of germline testing for participants receiving care at University of California participating locations with a new or existing diagnosis of Pancreatic Neuroendocrine Neoplasms (PanNEN). This protocol is an extension of existing Genetic Testing Station efforts at University of California, San Francisco (UCSF)",[98],"Pancreatic Neuroendocrine Neoplasm",[100,101],"Genetic Assay","Biomarkers","2026-01-22",{"date":104,"type":105},"2026-01-26","ACTUAL",{"date":107,"type":105},"2023-04-07",{"date":109,"type":94},"2026-12-31",{"name":5,"class":6},3]